JAGX
Price
$1.62
Change
+$0.02 (+1.25%)
Updated
Aug 29, 01:53 PM (EDT)
Capitalization
3.48M
MRNA
Price
$24.06
Change
-$0.41 (-1.68%)
Updated
Aug 29, 02:28 PM (EDT)
Capitalization
9.52B
62 days until earnings call
Interact to see
Advertisement

JAGX vs MRNA

Header iconJAGX vs MRNA Comparison
Open Charts JAGX vs MRNABanner chart's image
Jaguar Health
Price$1.62
Change+$0.02 (+1.25%)
Volume$905
Capitalization3.48M
Moderna
Price$24.06
Change-$0.41 (-1.68%)
Volume$9.69K
Capitalization9.52B
JAGX vs MRNA Comparison Chart in %
Loading...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAGX vs. MRNA commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and MRNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (JAGX: $1.60 vs. MRNA: $24.47)
Brand notoriety: JAGX: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 177% vs. MRNA: 114%
Market capitalization -- JAGX: $3.48M vs. MRNA: $9.52B
JAGX [@Biotechnology] is valued at $3.48M. MRNA’s [@Biotechnology] market capitalization is $9.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 1 FA rating(s) are green whileMRNA’s FA Score has 0 green FA rating(s).

  • JAGX’s FA Score: 1 green, 4 red.
  • MRNA’s FA Score: 0 green, 5 red.
According to our system of comparison, JAGX is a better buy in the long-term than MRNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 3 TA indicator(s) are bullish while MRNA’s TA Score has 4 bullish TA indicator(s).

  • JAGX’s TA Score: 3 bullish, 5 bearish.
  • MRNA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both JAGX and MRNA are a bad buy in the short-term.

Price Growth

JAGX (@Biotechnology) experienced а -12.09% price change this week, while MRNA (@Biotechnology) price change was -6.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.09%. For the same industry, the average monthly price growth was +15.11%, and the average quarterly price growth was +29.36%.

Reported Earning Dates

MRNA is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-1.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($9.52B) has a higher market cap than JAGX($3.48M). MRNA YTD gains are higher at: -41.150 vs. JAGX (-93.663). JAGX has higher annual earnings (EBITDA): -38.75M vs. MRNA (-2.72B). MRNA has more cash in the bank: 5.13B vs. JAGX (2.21M). JAGX has less debt than MRNA: JAGX (30.5M) vs MRNA (741M). MRNA has higher revenues than JAGX: MRNA (3.06B) vs JAGX (11.8M).
JAGXMRNAJAGX / MRNA
Capitalization3.48M9.52B0%
EBITDA-38.75M-2.72B1%
Gain YTD-93.663-41.150228%
P/E Ratio0.04N/A-
Revenue11.8M3.06B0%
Total Cash2.21M5.13B0%
Total Debt30.5M741M4%
FUNDAMENTALS RATINGS
JAGX vs MRNA: Fundamental Ratings
JAGX
MRNA
OUTLOOK RATING
1..100
5555
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
4885

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (12) in the Pharmaceuticals Generic industry is somewhat better than the same rating for MRNA (57) in the Biotechnology industry. This means that JAGX’s stock grew somewhat faster than MRNA’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as MRNA (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to MRNA’s over the last 12 months.

JAGX's SMR Rating (100) in the Pharmaceuticals Generic industry is in the same range as MRNA (100) in the Biotechnology industry. This means that JAGX’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's Price Growth Rating (65) in the Biotechnology industry is in the same range as JAGX (97) in the Pharmaceuticals Generic industry. This means that MRNA’s stock grew similarly to JAGX’s over the last 12 months.

MRNA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that MRNA’s stock grew similarly to JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXMRNA
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XNET7.040.36
+5.39%
Xunlei Limited
PRLD1.310.03
+2.34%
Prelude Therapeutics
SMA36.810.32
+0.88%
Smartstop Self Storage REIT Inc
TIVC3.090.02
+0.65%
Tivic Health Systems Inc
UHS181.22-1.19
-0.65%
Universal Health Services